MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study To guage multiple intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Key demo targets were To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers, when one of the exploratory objectives https://phenylephrinehydrochlorid33210.shotblogs.com/top-m3541-secrets-44961011